Exosome-based multivalent vaccine: achieving potent immunization, broadened reactivity, and strong T-cell responses with nanograms of proteins
Currently approved vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) have focused solely on the spike protein to provide immunity. The first …
(SARS-CoV-2) have focused solely on the spike protein to provide immunity. The first …
Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
M Cacciottolo, Y Li, JB Nice, MJ LeClaire, R Twaddle… - PLoS …, 2023 - journals.plos.org
Exosomes are emerging as potent and safe delivery carriers for use in vaccinology and
therapeutics. A better vaccine for severe acute respiratory syndrome coronavirus 2 (SARS …
therapeutics. A better vaccine for severe acute respiratory syndrome coronavirus 2 (SARS …
Possibility of exosome‑based coronavirus disease 2019 vaccine
KH Yoo, N Thapa, BJ Kim, JO Lee… - Molecular …, 2022 - spandidos-publications.com
Abstract Coronavirus disease 2019 (COVID‑19) is a global pandemic that can have a long‑
lasting impact on public health if not properly managed. Ongoing vaccine development trials …
lasting impact on public health if not properly managed. Ongoing vaccine development trials …
Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination
Background In less than a year from its zoonotic entry into the human population, SARS-
CoV-2 has infected more than 45 million people, caused 1.2 million deaths, and induced …
CoV-2 has infected more than 45 million people, caused 1.2 million deaths, and induced …
A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta …
L Jiang, TAP Driedonks, WSP Jong… - Journal of …, 2022 - Wiley Online Library
Several vaccines have been introduced to combat the coronavirus infectious disease‐2019
(COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS …
(COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS …
Cutting edge: circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer–BioNTech) vaccination prior to development of antibodies: a novel …
Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causes severe acute
respiratory syndrome. mRNA vaccines directed at the SARS-CoV-2 spike protein resulted in …
respiratory syndrome. mRNA vaccines directed at the SARS-CoV-2 spike protein resulted in …
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine
The first two mRNA vaccines against infection by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that were approved by regulators require a cold chain and …
coronavirus 2 (SARS-CoV-2) that were approved by regulators require a cold chain and …
Exosome-based vaccines: history, current state, and clinical trials
P Santos, F Almeida - Frontiers in immunology, 2021 - frontiersin.org
Extracellular vesicles (EVs) are released by most cell types as part of an intracellular
communication system in crucial processes such as inflammation, cell proliferation, and …
communication system in crucial processes such as inflammation, cell proliferation, and …
Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and …
F Ferrantelli, C Chiozzini, F Manfredi, A Giovannelli… - Vaccines, 2021 - mdpi.com
Most advanced vaccines against severe acute respiratory syndrome coronavirus (SARS-
CoV)-2 are designed to induce antibodies against spike (S) protein. Differently, we …
CoV)-2 are designed to induce antibodies against spike (S) protein. Differently, we …
Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants
L van Oosten, JJ Altenburg, C Fougeroux… - MBio, 2021 - Am Soc Microbiol
Vaccines pave the way out of the SARS-CoV-2 pandemic. Besides mRNA and adenoviral
vector vaccines, effective protein-based vaccines are needed for immunization against …
vector vaccines, effective protein-based vaccines are needed for immunization against …